Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
gMendel logo — Transforming the diagnosis of genetic disorders for better d...

gMendel

Transforming the diagnosis of genetic disorders for better disease management

Founded 2020 Denmark Denmark 9 employees

General Information

Company Name gMendel
Founded Year 2020
Location Denmark Denmark +1
Employees 9
Social

Get notified when gMendel moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About gMendel

gMendel is an AI-powered, vertically-integrated IVD certified technology that aims to transform the diagnosis of genetic disorders for better disease management. With over 350 million people worldwide suffering from over 10,000 genetic disorders and rare diseases, but less than 500 of these diseases having an approved treatment, there is a significant unmet clinical need for better, faster, and more affordable companion diagnostics for rare diseases. The societal burden of rare diseases exceeds €2 trillion, underscoring the urgency for precision treatments. The current diagnosis of rare diseases takes an average of 7 years, is costly, complex, and leaves many patients undiagnosed. gMendel® offers an end-to-end cloud-based technology that utilizes AI for the accurate, fast, and affordable diagnosis of multiple rare diseases and beyond. Having obtained the CE mark under EU IVDD in 2022, gMendel® is the world’s first IVD certified technology for human genetic disorders utilizing long-read sequencing technology and AI. The technology has also achieved Proof of Concept to detect deletions, insertions, and point mutations by conducting whole exome sequencing or DNA region customization. The company is currently in the process of commercializing its technology for companion diagnostics for Anemia, Epilepsy, Cystic Fibrosis, and Spinal Muscular Atrophy. gMendel®'s novel combination of genomics and AI sets it apart, making its technology better, faster, and more affordable than existing offerings in the companion diagnostics market.

Taxonomy: Genetic Diagnostics, Rare Diseases, IVD Technology, AI in Healthcare, Companion Diagnostics, Long Read Sequencing, Precision Medicine, Genomics, Anemia Diagnostics, Epilepsy Diagnostics, Cystic Fibrosis Diagnostics, Spinal Muscular Atrophy Diagnostics

No funding data available for gMendel yet.

Get notified when gMendel raises funding

gMendel Alternatives & Competitors

gMendel vs
MEDGENOME
MEDGENOME India

Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions

Series D
1011 employees
Biotechnology, Health Care
gMendel vs
Day Zero Diagnostics, Inc
Day Zero Diagnostics, Inc United States

The future of infectious disease diagnostics starts at Day Zero.

Unknown
64 employees
Biotechnology, Health Care
gMendel vs
Senzo Health
Senzo Health United States

PCR-Accurate Lateral Flow Testing

Undisclosed
8 employees
Biotechnology, Health Care

FAQ About gMendel

Transforming the diagnosis of genetic disorders for better disease management
gMendel was founded in 2020.
gMendel is headquartered in Denmark.
gMendel has approximately 9 employees.
Top alternatives and competitors to gMendel include MEDGENOME, Day Zero Diagnostics, Inc, Senzo Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
gMendel and MEDGENOME are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors gMendel and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy